Bristol-Myers Squibb Company (BMY) Position Boosted by Quantitative Systematic Strategies LLC

Gladys Abbott
June 12, 2017

Covington Capital Management now owns 149,160 shares of the biopharmaceutical company's stock worth $8,043,000 after buying an additional 7,260 shares during the last quarter. Vontobel Asset Management has 2.33 million shares. ANDREOTTI LAMBERTO had sold 34,000 shares worth $1.91M on Monday, March 27. Another trade for 347,000 shares valued at $7.22 million was made by FRIEDMAN BRIAN P on Monday, March 6. It is down 70.12% since June 12, 2016 and is uptrending. It has outperformed by 4.18% the S&P500.

More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Marketwatch.com which released: "Bristol-Myers Squibb reports data from phase 1/2 trial for cancers associated ..." on June 02, 2017, also Seekingalpha.com with their article: "Bristol-Myers Fails To Stem The Losses" published on June 07, 2017, Nasdaq.com published: "Sector Gamma As Buys Bristol-Myers Squibb Company, Perrigo Co PLC, Abbott ..." on June 09, 2017. Nelson Roberts Investment Limited Liability Com holds 0.05% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 2,400 shares. The Courage Capital Management Llc holds 280,400 shares with $8.37 million value, down from 300,000 last quarter. Bristol now has $90.36 billion valuation. The stock increased 1.70% or $0.9 on June 9, reaching $53.75. About 978,117 shares traded. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/06/12/dubuque-bank-trust-co-increases-position-in-bristol-myers-squibb-company-bmy.html. It has underperformed by 39.89% the S&P500. Prospector Partners Llc who had been investing in Renaissancere Holdings Ltd for a number of months, seems to be bullish on the $5.83 billion market cap company. Corporate insiders own 0.23% of the company's stock. BMY has the outstanding shares of 1662.00and its EPS growth ratio for the past five years was 4.20%.

Its latest closing price kept its distance from the SMA50 at -0.73% and -0.39% compared with the SMA 20 while it was down/up -1.98% from the average-price of 200 days. 51 funds opened positions while 83 raised stakes. 19,792 are owned by Court Place Advsrs Limited Liability Corporation. Following the sale, the senior vice president now owns 55,637 shares of the company's stock, valued at approximately $3,187,443.73. Swiss Commercial Bank accumulated 0.43% or 4.65M shares. 59,082 are held by Citigroup Incorporated. Prospector Prns Ltd holds 95,884 shares. VVPR's SI was 1,600 shares in June as released by FINRA. The institutional investor owned 17,289 shares of the biopharmaceutical company's stock after buying an additional 1,307 shares during the period. Swiss National Bank & Trust has invested 0.07% in RenaissanceRe Holdings Ltd. (NYSE:RNR). Brown Advisory reported 315,718 shares. Gamco Inc Et Al invested 0.26% of its portfolio in Cheesecake Factory Inc (NASDAQ:CAKE). During the same quarter in the prior year, the firm earned $0.74 EPS. 9,500 were reported by Pacad Investment Limited.

Since March 1, 2017, it had 7 insider buys, and 1 insider sale for $21.82 million activity. ZURZOLO DEBBY R had sold 6,000 shares worth $354,892 on Tuesday, May 23. Benjamin F Edwards & holds 13,980 shares. $23,288 worth of Cheesecake Factory Inc (NASDAQ:CAKE) shares were bought by PITTAWAY DAVID BRUCE. Inc. now owns 46,458 shares of the biopharmaceutical company's stock worth $2,505,000 after buying an additional 349 shares during the last quarter. 12,514 shares valued at $773,653 were sold by KRANSDORF JEROME I on Tuesday, March 7.

More news: Omnicom Group Inc. (OMC), Carbonite, Inc. (CARB) — Stocks Trend Overview

Reliance Trust decreased Bristol (BMY) stake by 13.23% reported in 2016Q4 SEC filing. The rating was downgraded by Berenberg to "Hold" on Thursday, August 11. The rating was upgraded by Argus Research to "Buy" on Tuesday, November 15. The stock has "Buy" rating by Jefferies on Monday, December 19. The stock of Cheesecake Factory Inc (NASDAQ:CAKE) earned "Sell" rating by Stifel Nicolaus on Tuesday, July 26. The rating was upgraded by Jefferies to "Buy" on Monday, December 19. Last session Bristol-Myers Squibb Company RSI was seen at 50.18. Therefore 41% are positive. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.95 earnings per share for the current fiscal year. The market capitalization of the company is at $89.33 Billion. BMO Capital Markets lowered Bristol-Myers Squibb Company from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company.in a research note on Wednesday, May 3rd. Piper Jaffray Companies reaffirmed a "neutral" rating and set a $60.00 price target on shares of Bristol-Myers Squibb Company in a research note on Wednesday, March 8th. The stock presently has a consensus rating of "Hold" and a consensus price target of $62.41. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has "Equal-Weight" rating given on Friday, August 5 by Morgan Stanley. Barclays Capital maintained the shares of BMY in report on Friday, April 29 with "Equal Weight" rating.

Investors sentiment increased to 0.83 in 2016 Q4. Its down 0.16, from 1.13 in 2016Q3. It dived, as 86 investors sold BMY shares while 529 reduced holdings.

Other hedge funds have also recently added to or reduced their stakes in the company. British Columbia Investment Mgmt owns 35,006 shares. Salzhauer Michael holds 2,786 shares. Geode Ltd Liability Corp stated it has 0.43% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). The analysts estimated EPS for the higher end at 0.78 and lower end at 0.68 while the year ago reported earnings per share was 0.82. Bristol-Myers Squibb Company had 37 analyst reports since July 28, 2015 according to SRatingsIntel. Ronna Sue Cohen invested in 1.45% or 32,180 shares. Gamco Invsts Et Al holds 0.19% or 523,672 shares in its portfolio. Blackrock Inc has invested 0.33% in Bristol-Myers Squibb Co (NYSE:BMY). Dodge & Cox acquired a new stake in Bristol-Myers Squibb Company during the fourth quarter valued at approximately $1,316,815,000.

Since February 27, 2017, it had 1 insider purchase, and 6 sales for $9.91 million activity. Haverford Trust has 0.11% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 77,094 shares.

Other reports by LeisureTravelAid

Discuss This Article

FOLLOW OUR NEWSPAPER